| Literature DB >> 25019943 |
Eric L Voorn1, Merel A Brehm2, Anita Beelen2, Arnold de Haan3, Frans Nollet2, Karin H L Gerrits3.
Abstract
OBJECTIVE: To assess the reliability of contractile properties of the knee extensor muscles in 23 individuals with post-polio syndrome (PPS) and 18 age-matched healthy individuals.Entities:
Mesh:
Year: 2014 PMID: 25019943 PMCID: PMC4096590 DOI: 10.1371/journal.pone.0101660
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Subject characteristics.
| PPS ( | Control ( | |
|
| ||
| Gender (male/female) | 9/14 | 6/12 |
| Age (yrs) | 59.9±6.3 | 58.5±6.8 |
| Weight (kg) | 77.3±12.7 | 74.7±8.5 |
| BMI (kg/m2) | 26.4±2.8 | 24.7±2.9 |
|
| ||
| Age at acute polio (yrs) | 1.0 (0–9) | - |
| Time since new symptoms (yrs) | 15 (3–33) | - |
| Present walking distance | 3 (2–4) | - |
| Measured leg (most/less affected) | 13/10 | - |
Values for demographic data are mean ± SD; values for polio characteristics are median (range).
Abbreviations: PPS, post-polio syndrome; BMI, body mass index.
*Walking distance was defined as the daily distance walked and was classified in 4 categories: 1 (indoors only), 2 (around the house), 3 (seldom >1 km), and 4 (regularly >1 km).
Results on test and retest for individuals with PPS and healthy subjects.
| n | Test (T1) | Retest (T2) | Δ T2–T1 | 95% CIΔ | ICC2,1 (95% CIICC) | |
|
| ||||||
|
| ||||||
| PPS | 19 | 48.0±10.3 | 47.7±11.6 | −0.28±4.90 | −2.64–2.08 | 0.90 (0.77–0.96) |
| Control | 16 | 51.6±12.9 | 53.7±12.2 | 2.06±4.98 | −0.60–4.71 | 0.91 (0.77–0.97) |
|
| ||||||
|
| ||||||
| PPS | 23 | 116.8±47.3 | 114.2±48.9 | −2.54±12.51 | −7.95–2.86 | 0.97 (0.92–0.99) |
| Control | 18 | 177.7±33.8 | 176.1±32.7 | −1.67±9.10 | −6.20–2.85 | 0.96 (0.91–0.99) |
|
| ||||||
| PPS | 23 | 15.4±7.9 | 15.0±6.4 | −0.35±6.55 | −3.18–2.48 | 0.59 (0.24–0.81) |
| Control | 18 | 16.6±9.4 | 15.2±8.3 | −1.39±6.11 | −4.43–1.65 | 0.76 (0.48–0.90) |
|
| ||||||
| PPS | 23 | 125.0±8.3 | 125.2±8.4 | 0.22±3.92 | −1.48–1.91 | 0.89 (0.77–0.95) |
| Control | 18 | 122.6±8.2 | 125.2±7.6 | 2.67±4.23 | 0.56–4.77 | 0.82 (0.49–0.93) |
|
| ||||||
| PPS | 23 | 28.0±3.5 | 28.9±3.5 | 0.87±4.69 | −1.16–2.90 | 0.10 (−0.33–0.48) |
| Control | 18 | 31.9±6.1 | 30.6±5.1 | −1.33±4.80 | −3.72–1.06 | 0.63 (0.25–0.84) |
The score on the two visits and the difference (Δ) are presented as mean ± SD.
Missing data are due to the difficulty of some subjects to relax the leg during the stimulated protocol, resulting in unworkable signals, and leading to different numbers of observations for different parameters.
Abbreviations: ICC, intraclass correlation coefficient; CI, confidence interval; PPS, post-polio syndrome; RT50, relaxation time 50%; MVT, maximal voluntary torque; Nm, Newton meter; MRTD, maximal rate of torque development; RT25, relaxation time 25%; ms, milliseconds.
Results for measurement error for individuals with PPS and healthy subjects.
|
| SEM (% of mean) | ALoA | CV | RLoA | |
|
| |||||
|
| |||||
| PPS | −0.065 ( | 3.38 (7.1%) | −9.9–9.3 | - | - |
| Control | −0.059 ( | 3.70 (7.0%) | −7.7–11.8 | - | - |
|
| |||||
|
| |||||
| PPS | −0.138 ( | 8.83 (7.6%) | −27.1–22.0 | - | - |
| Control | −0.033 ( | 6.36 (3.6%) | −19.5–16.2 | - | - |
|
| |||||
| PPS | 0.518 | - | - | 30.0% | 0.42–2.28 |
| Control | 0.399 | - | - | 26.8% | 0.44–1.96 |
|
| |||||
| PPS | 0.009 ( | 2.71 (2.2%) | −7.5–7.9 | - | - |
| Control | −0.042 ( | 3.46 (2.8%) | −5.6–11.0 | - | - |
|
| |||||
| PPS | 0.123 ( | - | - | 11.6% | 0.75–1.42 |
| Control | 0.338 ( | - | - | 10.2% | 0.73–1.27 |
Abbreviations: SEM, standard error of measurement; ALoA, absolute limits of agreement; CV, coefficient of variation; RLoA, ratio limits of agreement; PPS, post-polio syndrome; RT50, relaxation time 50%; MVT, maximal voluntary torque; Nm, Newton meter; MRTD, maximal rate of torque development; RT25, relaxation time 25%; ms, milliseconds.
*Significant correlation (p<.05, two tailed) using Kendall's τ-correlation coefficient.
Figure 1The Bland-Altman graphs with the differences between test sessions 2 and 1 (test 2 minus test 1) plotted against the means of the 2 test sessions for the five studied variables, for patients with PPS (o) and healthy subjects (•).
Sample size estimation for an effect study to detect improvement in fatigue resistance between 2 independent groups of individuals with PPS.
| Minimal number of subjects per group needed (n) | |
|
| |
| 10% | 22 |
| 15% | 10 |
| 20% | 6 |
We calculated the minimal number of subjects per group (n) needed to find a significant change of fatigue resistance from n>2(Zα+Zβ)2 σ2/δ2, with Z values based on tables of standard normal curves (Zα+Zβ = 3.242 for a = .05 and b = .10), σ as the standard deviation of the difference (4.90%), and δ as the minimal difference in effect that is considered of clinical interest. Because it is unknown what change is considered clinically relevant we estimated sample size based on different change scores (i.e. 10%, 15% and 20%).